Lenvatinib combined with PD-1 inhibitor plus Gemox chemotherapy versus plus HAIC for advanced biliary tract cancer

奥沙利铂 医学 化疗 内科学 不利影响 临床终点 胃肠病学 癌症 吉西他滨 随机对照试验 结直肠癌
作者
Ting Zhang,Chengpei Zhu,Nan Zhang,Longhao Zhang,Shanshan Wang,Ziyu Xun,Yiyao Xu,Xiaobo Yang,Xin Lü,Haitao Zhao
出处
期刊:International Immunopharmacology [Elsevier BV]
卷期号:129: 111642-111642 被引量:15
标识
DOI:10.1016/j.intimp.2024.111642
摘要

To compare the treatment efficacy and safety of lenvatinib and programmed cell death 1 (PD-1) inhibitor combined with oxaliplatin plus gemcitabine (Gemox) chemotherapy or hepatic arterial infusion chemotherapy (HAIC) for patients with advanced biliary tract cancer (BTC). This study involved 86 patients with advanced BTC receiving PD-1 inhibitor and lenvatinib combined with HAIC (P-L-H group) or Gemox chemothrapy (P-L-G group). Propensity score matching (PSM) (1:1) analysis was used to balance potential bias. The primary endpoints were overall survival (OS) and progression-free survival (PFS), whereas the secondary endpoints were objective response rate (ORR), disease control rate (DCR), and safety. After PSM, a total of 60 patients were enrolled with 30 in the P-L-G group and 30 in the P-L-H group. The median PFS was significantly longer with P-L-G group (13.7 versus 6.0 months, p < 0.0001) than with the P-L-H group. The median OS was 23.8 months in the P-L-G group versus 11.6 months in the P-L-H group (p < 0.0001). Patients in the P-L-G group exhibited a better ORR (73.3 % vs 30 %, p = 0.002) compared to the P-L-H group. The DCR was the same in both groups, 96.7 %, respectively. The P-L-G group had a higher incidence of grade 3–4 AEs than the P-L-H group. However, there was no significant difference in the any grade or grade 3–4 of AEs between the two groups. PD-1 inhibitor plus lenvatinib and Gemox are promising first-line regimens for the treatment of advanced BTC in the multicenter retrospective real-world study.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
茄子完成签到,获得积分10
刚刚
LL完成签到 ,获得积分10
刚刚
wyc发布了新的文献求助10
刚刚
贺雪完成签到,获得积分10
刚刚
QB完成签到,获得积分10
1秒前
Jasper的应助被anchor采纳,获得10
1秒前
1秒前
典雅的彤完成签到,获得积分10
2秒前
2秒前
2秒前
云淡风轻发布了新的文献求助10
2秒前
zsss完成签到 ,获得积分10
2秒前
2秒前
sufu_jony的应助被单身的凡雁采纳,获得10
3秒前
3秒前
唐飒发布了新的文献求助10
3秒前
唐飒发布了新的文献求助10
3秒前
深情安青的应助被一见采纳,获得10
3秒前
唐飒发布了新的文献求助10
3秒前
索大学术完成签到,获得积分10
3秒前
情怀的应助被土豆采纳,获得10
3秒前
snow完成签到,获得积分10
4秒前
longchb完成签到,获得积分10
4秒前
4秒前
耿耿于怀完成签到,获得积分10
5秒前
5秒前
5秒前
5秒前
mof发布了新的文献求助10
5秒前
ynglik完成签到,获得积分10
6秒前
咎如天发布了新的文献求助10
6秒前
6秒前
yunshan完成签到,获得积分10
6秒前
十七完成签到,获得积分10
6秒前
天道完成签到,获得积分10
6秒前
7秒前
NexusExplorer的应助被Jenny采纳,获得10
7秒前
xiangpica完成签到,获得积分10
7秒前
唐飒发布了新的文献求助10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173962
求助须知:如何正确求助?哪些是违规求助? 9566073
关于积分的说明 21784460
捐赠科研通 7768184
什么是DOI,文献DOI怎么找? 3431663
关于科研通互助平台的介绍 2555907
邀请新用户注册赠送积分活动 2476936